New Therapies for Advanced Parkinson's Disease
October 29, 2010
Durham, North Carolina
Parkinson's disease (PD) is a major neurological disorder that affects tens of millions of people worldwide; it is a chronic, progressive degenerative disorder of the central nervous system that leads to severe disability in many patients, and is a major healthcare issue, especially in the elderly. PD is caused by the loss of normal dopamine signaling in the brain, resulting in a range of characteristic movement, mobility and posture symptoms. While mainstay therapies, such as levodopa or dopamine agonists, provide significant initial benefit to patients with PD, there is increasing need for new therapies for this disorder. This course provided this information in two ways: a didactic lecture setting with ample time for questions and answers, and workshop, case-based presentations to stimulate and amplify concepts presented in the early sessions.
This course was recorded for webcasting.
Participants in this activity learned to:
- Explain their approach for addressing the motor complications of advanced Parkinson's disease;
- Develop a strategy to incorporate the newer therapies that are useful for treatment of motor complications;
- Describe their treatment plan for these non-motor complications in PD;
- Discuss the rationale for treatment in case-based examples of advanced PD patients with motor and non-motor complications.
This course was recommended for Movement Disorder specialists, general neurologists, primary care physicians and junior investigators.
Supported by educational grants from the following: